VectivBio (NASDAQ:VECT) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of VectivBio (NASDAQ:VECTGet Rating) from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need. VectivBio Holding AG is based in BASEL, Switzerland. “

Shares of NASDAQ:VECT opened at $5.01 on Friday. VectivBio has a fifty-two week low of $2.74 and a fifty-two week high of $23.37. The stock has a 50-day simple moving average of $5.30.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VECT. Wells Fargo & Company MN purchased a new stake in shares of VectivBio during the 2nd quarter valued at about $43,000. Geode Capital Management LLC increased its holdings in VectivBio by 29.7% in the 4th quarter. Geode Capital Management LLC now owns 23,054 shares of the company’s stock worth $113,000 after acquiring an additional 5,274 shares in the last quarter. Canaan Partners XI LLC purchased a new stake in VectivBio in the 4th quarter worth approximately $182,000. Bank of America Corp DE increased its holdings in VectivBio by 10,635.9% in the 4th quarter. Bank of America Corp DE now owns 72,682 shares of the company’s stock worth $357,000 after acquiring an additional 72,005 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in VectivBio in the 2nd quarter worth approximately $1,110,000. 70.08% of the stock is owned by hedge funds and other institutional investors.

About VectivBio (Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy.

Further Reading

Get a free copy of the Zacks research report on VectivBio (VECT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VectivBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VectivBio and related companies with MarketBeat.com's FREE daily email newsletter.